Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719
Journal article published in 2014 by
Udai Banerji,
Alan David Smith,
Andrea Zivi,
David Lorente 
,
Karim Rihawi,
Nina Tunarlu,
Adam Stewart,
Parames Thavasu,
Audrey Kaag,
Rajkumar Radhakrishnan,
Heiko Maacke,
L. Rhoda Molife,
Stanley B. Kaye,
Johann Sebastian Do Bono
,
Karim Rihawi,
Nina Tunarlu,
Adam Stewart,
Parames Thavasu,
Audrey Kaag,
Rajkumar Radhakrishnan,
Heiko Maacke,
L. Rhoda Molife,
Stanley B. Kaye,
Johann Sebastian Do Bono
